A recent study reported that the recruitment and infiltration of CAR-T cells in NSCLC tumors can be enhanced when combined with a PD-1 inhibitor and immunogenic chemotherapy (159). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.